The younger Damadian worked with Fonar for 16 years, eventually becoming veep of operations. He formed Fonar subsidiary Health Management Corporation of America, which manages medial and diagnostic imaging offices. HMCA generated approximately $40 million in revenue, Fonar said.
“As far as I’m concerned, making Tim the president and CEO of Fonar will be a seamless transition. For all practical purposes he and his management team have been providing Fonar with the vision, direction, and management skills accounting for Fonar’s success over the past six years. He’s also been heavily involved with development of Fonar technology, where his keen understanding of the MRI marketplace and the needs and trends of MRI practitioners has been invaluable in helping me to guide the company’s R&D program. Tim is the perfect fit to ensure Fonar’s success for years to come,” former CEO Dr. Damadian said in a press release.
Timothy Damadian left Fonar and formed Integrity Healthcare Management in 2001, which was sold to Health Diagnostics in 2007. Damadian returned to Fonar as a consultant in 2010.
Former CEO and founder Dr. Damadian will remain with the company as board chair, the Melville, N.Y.-based company said.
“It is, of course, a great honor that my father has entrusted me with this responsibility. As we all know, Dr. Damadian founded this company and has tirelessly devoted himself to it for nearly 40 years. I’m delighted that he remains chairman of the board and will continue to concentrate on R&D, develop exciting and innovative new products, and advance the industry with indispensible MRI applications. Over all those years, his genius and passion for science and technology is as vibrant as it was back in 1971 when he conceived the idea of an MR scanner that could scan the human body. Then, in 1977, he built the very first whole-body MR scanner, which, in July of that year, produced the first human MR image,” CEO Timothy Damadian said in prepared remarks.
Vestagen makes Bold choice with ex-Vascular Pathways as new CEO
Vestagen said yesterday it tapped Bill Bold, the former CEO of Vascular Pathways who headed a turnaround that led to a buyout by C.R. Bard (NYSE:BCR). Bold replaces Dale Pfost, who will remain board chair.
Prism Medical promotes former Getinge, Baxter exec to the corner office
Prism Medical said last week it is promoting its current senior veep and former Getinge (PINK:GETI B) and Baxter (NYSE:BAX) exec Ross Scavuzzo to CEO, replacing Andrew McIntyre as CEO and John Charles, who served as interim CEO. McIntyre will remain as board chair, and Charles as vice chair.
Dune Medical picks med device vet Chmura as prez
Dune Medical Devices said Monday it picked Lori Chmura, current veep of North American sales and former exec with Maquet, Medtronic (NYSE:MDT) and Cordis, as its new president.
Admedus taps 25-year pharma vet Paterson for board chair
Admedus (ASX:AHZ) said yesterday it tapped 25-year pharma vet Wayne Paterson as its new board chair, with former chair Chris Catlow retiring from the position.
- Turnpoint Medical devices adds Bonderud, Hulse and York to board
- Abiomed expands board, adds Rivet and Van Gord
- Keystone Technologies snags healthcare IT vet Bell for CIO
- Insulet expands board to 9 with appointment of Lemoine
- ALR Technologies prez Smith bows out over budget cuts
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.